HCP Live October 1, 2023
Tim Smith

This study indicated the potential of PDLs as a strategy for those that have HDHP-HSAs to address both patient access and affordability of asthma care.

A preventative drug list (PDL) is linked with more affordable asthma medication as well as greater use of controller medication, according to recent findings, though PDLs do not lead to differences in outcomes for clinical asthma.1

This new data was the result of a recent case-control study which aimed to assess the effects of a PDL that provides exemption from out-of-pocket cost sharing for patients’ asthma medications on adverse outcomes, on their utilization, and on their out-of-pocket expenses.

The research was viewed as invaluable, given the varying results researchers have had in examining links between...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Which Side Will Makary Take In The Fight Over Weight Loss Drugs?
Expert Discusses Changes in Diabetes Care | APhA 2025
Big pharma’s grip on health care: time for change
Potential Challenges in Using ChatGPT for Pharmacy Services
Q&A: How Pharmacists Can Make a Difference Beyond the Counter

Share This Article